New Treatment For Painful Diabetic Neuropathy: Nevro (NVRO) Overview
TD Ameritrade Network
English - July 22, 2021 18:41 - 6 minutes - 34.9 MB - ★★★★★ - 23 ratingsNews Commentary News Business News business news news commentary news Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Chipotle (CMG) CFO Jack Hartung Talks Earnings, Growth, & Margins
Next Episode: Examining Airline Stocks / Earnings: LUV, AAL, UAL
The FDA recently approved Nevro (NVRO) treatment for chronic pain from Painful Diabetic Neuropathy (PDN). The treatment is called HFX™ and is now the only spinal cord stimulation system treatment for PDN that is approved by the FDA. Keith Grossman, Chairman and CEO of Nevro, discusses HFX™, as well as what this treatment means for diabetic patients. Nevro stock also hit an all-time high in December 2020. Tune in to find out more.